INmune Bio Inc. (NASDAQ: INMB) announced preclinical data demonstrating that its drug candidate INB03 enhanced the effectiveness of existing cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE